Table 2 Participant demographics and clinical characteristics for the Parkinson’s disease and healthy control groups at time of [18F]Florbetaben scan
From: Beta amyloid deposition and cognitive decline in Parkinson’s disease: a study of the PPMI cohort
Parkinson’s disease | Healthy controls | |
|---|---|---|
Population (female) | 25 (4 female) | 30 (17 female)a |
Age (years) | 67.56 [8.74] | 65.67 [5.80] |
Education (years) | 16.20 [2.90] | 17.40 [3.37] |
MoCA | 27.04 [2.46] | 28.20 [1.37]b |
GDS | 5.06 [1.03] | 4.93 [0.94] |
Disease duration (months) | 50.04 [16.91] | n/a |
UPDRS-III ON | 25.70 [8.94] | n/a |
UPDRS-III OFF | 29.92 [8.89] | n/a |
LEDD (mg) | 345.19 [217.39] | n/a |